FOLH1 and posterior cortical atrophy: In contrast, no increased PSMA expression was found in a study of 26 metastatic hormone-resistant PCa patients after a median of 3 months under Enzalutamide or Abiraterone [27] and a decreased PSMA expression was reported in a retrospective analysis of 10 hormone-resistant patients following start of ADT [28].